PURPOSE: To present the long-term outcome of high-risk prostate cancer patients treated by radical retropubic prostatectomy (RRP) and stage-dependent adjuvant androgen deprivation therapy. PATIENTS AND METHODS: Between 1989 and 2005, 2,655 patients underwent RRP by 9 surgeons. All cases (n = 372) with high-risk prostate cancer (serum PSA >20 ng/ml, and/or clinical stage T2c or greater, and/or biopsy Gleason score 8 or greater) were identified and analyzed retrospectively. RESULTS: At 5 and 10 years, cancer-specific survival was 91.3 and 87.2%; overall survival was 84.3 and 72.1%; biochemical progression-free survival (BPFS) was 76.6 and 56.2%; clinical progression-free survival was 86.2 and 79.9%. Kaplan-Meier analysis showed significant differences with respect to pathological stage and Gleason score for cancer-specific survival, BPFS and clinical progression-free survival. In multiple analysis, the only preoperative predictor of BPFS at the 5% level was clinical stage (p = 0.0055). CONCLUSION: In patients with high-risk prostate cancer and a life expectancy of more than 10 years, RRP with stage-dependent adjuvant androgen deprivation therapy is a viable alternative to radiation therapy. Copyright (c) 2010 S. Karger AG, Basel.
PURPOSE: To present the long-term outcome of high-risk prostate cancerpatients treated by radical retropubic prostatectomy (RRP) and stage-dependent adjuvant androgen deprivation therapy. PATIENTS AND METHODS: Between 1989 and 2005, 2,655 patients underwent RRP by 9 surgeons. All cases (n = 372) with high-risk prostate cancer (serum PSA >20 ng/ml, and/or clinical stage T2c or greater, and/or biopsy Gleason score 8 or greater) were identified and analyzed retrospectively. RESULTS: At 5 and 10 years, cancer-specific survival was 91.3 and 87.2%; overall survival was 84.3 and 72.1%; biochemical progression-free survival (BPFS) was 76.6 and 56.2%; clinical progression-free survival was 86.2 and 79.9%. Kaplan-Meier analysis showed significant differences with respect to pathological stage and Gleason score for cancer-specific survival, BPFS and clinical progression-free survival. In multiple analysis, the only preoperative predictor of BPFS at the 5% level was clinical stage (p = 0.0055). CONCLUSION: In patients with high-risk prostate cancer and a life expectancy of more than 10 years, RRP with stage-dependent adjuvant androgen deprivation therapy is a viable alternative to radiation therapy. Copyright (c) 2010 S. Karger AG, Basel.
Authors: Maria Schubert; Steven Joniau; Paolo Gontero; Susanne Kneitz; Claus-Jürgen Scholz; Burkhard Kneitz; Alberto Briganti; R Jeffrey Karnes; Bertrand Tombal; Jochen Walz; Chao-Yu Hsu; Giansilvio Marchioro; Pia Bader; Chris Bangma; Detlef Frohneberg; Markus Graefen; Fritz Schröder; Paul van Cangh; Hein van Poppel; Martin Spahn Journal: Adv Urol Date: 2012-01-31
Authors: Christina Bluemel; Fraenze Linke; Ken Herrmann; Iva Simunovic; Matthias Eiber; Christian Kestler; Andreas K Buck; Andreas Schirbel; Thorsten A Bley; Hans-Juergen Wester; Daniel Vergho; Axel Becker Journal: EJNMMI Res Date: 2016-10-26 Impact factor: 3.138